| Enhertu (Trastuzumab Deruxtecan) |
|
HER2-directed ADC drug for several types of cancer including breast cancer, gastric cancer, lung cancer, and other metastatic sold tumors who have no other treatment options. The company has a global development and commercialization agreement with AstraZeneca for Enhertu. As per the agreement, Daiichi Sankyo and AstraZeneca share equally development and commercialization costs as well as profits from the drug worldwide, except in Japan where Daiichi Sankyo holds exclusive rights. In markets where Daiichi Sankyo is selling the product, AstraZeneca is entitled to receive a royalty (in Japan) or a share of costs and income (in other territories). Daiichi Sankyo is the licensor or owner of Enhertu. |
